Lentiviral Vectors Power Next Wave of In Vivo CAR-T Development

March 2026 — Global Biotech News

Lentiviral vector technology continues to play a central role in the evolution of CAR-T cell therapies, as researchers advance strategies aimed at delivering chimeric antigen receptor (CAR) constructs directly inside the body, potentially simplifying manufacturing and expanding patient access.

Recent research published in Signal Transduction and Targeted Therapy highlights emerging approaches for in vivo CAR-T generation, where viral vectors—including lentiviral systems—are used to genetically program immune cells directly within patients rather than through traditional ex vivo cell processing workflows.

Photo by Diane Serik on Unsplash

Moving Beyond Ex Vivo Manufacturing

Conventional CAR-T therapy requires collecting a patient’s T cells, genetically modifying them in specialized facilities—often using lentiviral vectors—expanding the engineered cells, and reinfusing them into the patient. While clinically effective, this process is complex, time-consuming, and costly.

The reviewed study outlines how advances in vector engineering, targeting specificity, and safety optimization may allow for direct in vivo delivery of CAR constructs, eliminating several logistical barriers inherent in centralized manufacturing models.

According to the authors, lentiviral vectors remain a cornerstone technology due to:

1. Stable gene integration and sustained CAR expression

2. High transduction efficiency in T cells

3. Established clinical safety profiles in approved gene therapies

However, challenges remain, including targeted delivery specificity, immune clearance of viral particles, and regulatory considerations.

Photo by National Cancer Institute on Unsplash

Engineering Improvements in Lentiviral Platforms

Researchers are exploring vector surface modifications, tissue-targeting strategies, and dosage optimization to enhance selective delivery to T cells while minimizing off-target effects.

The study also discusses comparative approaches using alternative delivery systems, but lentiviral vectors continue to be regarded as one of the most mature and clinically validated platforms for durable gene transfer in hematologic applications.

Photo by Ousa Chea on Unsplash

Expanding Access to Cell Therapy

If successfully translated into clinical practice, in vivo CAR-T approaches could:

1. Shorten treatment timelines

2. Reduce manufacturing costs

3. Expand therapy availability in regions lacking advanced cell-processing facilities

The publication underscores that while the technology is still under active investigation, the convergence of viral vector engineering and immunotherapy innovation represents a significant step toward scalable next-generation cell therapy models.

Source: 

Lentiviral vector and in vivo CAR-T delivery developments discussed in: 

Signal Transduction and Targeted Therapy (Springer Nature), 2026.